Oncofetal protein IGF2BP1 regulates IQGAP3 expression to maintain stem cell potential in cancer

Myint, Khine; Chuang, Linda Shyue Huey; Teh, Yu Xuan; Mawan, Nur Astiana; Shi, Edward Jizhong; Mok, Michelle Meng Huang; Nuttonmanit, Napat; Matsuo, Junichi; Liu, Ying; Yang, Henry; Okabe, Atsushi; Kaneda, Atsushi; Osato, Motomi; So, Jimmy Bok-Yan; Yong, Wei Peng; Tan, Patrick; Yeoh, Khay Guan; Ito, Yoshiaki

doi:10.1016/j.isci.2022.105194

Cited by 8 publications

(4 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 2 NA FLAG M2 Affinity Sigma-Aldrich A2220 Protein A/G Dynabeads Life Technologies 10015D Complete protease inhibitor Roche 11697498001 Halt Phosphatase inhibitor Thermo Fisher Scientific 78420 Phenylmethyl sulfonyl fluoride (PMSF) Sigma-Aldrich 10837091001 Dithiothreitol (DTT) Roche 10197777001 RNaseOUT Invitrogen 10777019 SUPERase IN Ambion AM2694 Proteinase K Thermo Fisher Scientific 26160 Phenol:Chloroform:Isoamyl Alcohol (25:24:1, v/v) Invitrogen 15593031 Actinomycin D Sigma-Aldrich A9415 Formaldehyde Sigma-Aldrich 252549 Critical commercial assays RNeasy kit Qiagen 74104 iScript cDNA synthesis kit Bio-Rad 1708890 iTaq Universal SYBR green kit Bio-Rad 1725150 QIAquick PCR purification kit Qiagen 28106 CellTiter-GLO Promega G9681 Pierce Bradford Assay kit Thermo Fisher Scientific 23236 Pierce BCA Protein Assay kit Thermo Fisher Scientific 23225 Deposited data RNA seq and RIP seq data Myint et al. 1 GSE196406 Experimental models: Cell lines ...…”

Section: Key Resources Tablementioning

confidence: 99%

See 1 more Smart Citation

Protocol for identification and validation of IGF2BP1 target genes in pluripotent human embryonic carcinoma cells

et al. 2023

Self Cite

View full text Add to dashboard Cite

Section: Key Resources Tablementioning

confidence: 99%

“…The raw and analyzed RIP-seq data are available in GEO under the accession number GSE196406 (Myint et al., 2022). 1 …”

Section: Resource Availabilitymentioning

confidence: 99%

Protocol for identification and validation of IGF2BP1 target genes in pluripotent human embryonic carcinoma cells

et al. 2023

Self Cite

View full text Add to dashboard Cite

“…Additionally, IF2BP1 can bind to other transcripts to regulate CSC activity, such as Irina A Elcheva et al reported that genetic or chemical inhibition of IF2BP1 decreases leukemia cells tumorigenicity and sensitizes leukemia cells to chemotherapeutic drugs through critical regulators of self-renewal (HOXB4, MYB, ALDH1A1) [62]. IF2BP1 can also bind to and stabilize m 6 A-modified IQAP3 transcript, which is an important stem cell factor in rapidly proliferating isthmus stem cells in the stomach, to sustain stem cell potential in cancer [63].…”

Section: The Effects Of M 6 a Recognition Protein On Csc Progressionmentioning

confidence: 99%

The roles of m6A RNA methylation modification in cancer stem cells: new opportunities for cancer suppression

Chen

Shi

et al. 2022

View full text Add to dashboard Cite

As a reversible post-transcriptional modification, N6-methyladeno sine is the most common form of RNA modification in eukaryotic mRNA. Cancer stem cells (CSCs), which are a subpopulation of cells with self-renewal ability and differentiation potential, have been regarded to be one of the roots of tumor occurrence, recurrence, and metastasis. Currently, numerous studies have demonstrated that m6A RNA modification is critically implicated in the regulation of CSCs stemness or the CSC-like traits of cancer cells. This review summarized the effects of m6A RNA modification-related enzymes and underlying mechanisms contributing to CSCs or cancer cell stemness, which may provide novel targets and research directions for the specifical elimination of CSCs or cancer cells with stemness.

show abstract

“…As an oncoprotein, FOXM1 activates a series of key genes for cell cycle and mitosis to promote the malignant proliferation of cancer cells [ 3 ]. FOXM1 is also involved in promoting metastasis and invasion of cancer cells [ 4 ] and maintaining the characteristics of cancer stem cells [ 5 , 6 ]. In terms of FOXM1-stimulating gene expression mechanisms, the FOXM1 DNA binding domain (DBD, 232-332aa) binds directly to its conserved RYAAAYA motif (FKH motif) in downstream gene promoters and thus activates their transcription [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

The development of an anti-cancer peptide M1-21 targeting transcription factor FOXM1

et al. 2023

View full text Add to dashboard Cite

Background Transcription factor FOXM1 is a potential target for anti-cancer drug development. An interfering peptide M1-21, targeting FOXM1 and FOXM1-interacting proteins, is developed and its anti-cancer efficacy is evaluated. Methods FOXM1 C-terminus-binding peptides are screened by in silico protocols from the peptide library of FOXM1 (1-138aa) and confirmed by cellular experiments. The selected peptide is synthesized into its D-retro-inverso (DRI) form by fusing a TAT cell-penetrating sequence. Anti-cancer activities are evaluated in vitro and in vivo with tumor-grafted nude mice, spontaneous breast cancer mice, and wild-type metastasis-tracing mice. Anti-cancer mechanisms are analyzed. Distribution and safety profiles in mice are evaluated. Results With improved stability and cell inhibitory activity compared to the parent peptide, M1-21 binds to multiple regions of FOXM1 and interferes with protein-protein interactions between FOXM1 and its various known partner proteins, including PLK1, LIN9 and B-MYB of the MuvB complex, and β-catenin. Consequently, M1-21 inhibits FOXM1-related transcriptional activities and FOXM1-mediated nuclear importation of β-catenin and β-catenin transcriptional activities. M1-21 inhibits multiple types of cancer (20 µM in vitro or 30 mg/kg in vivo) by preventing proliferation, migration, and WNT signaling. Distribution and safety profiles of M1-21 are favorable (broad distribution and > 15 h stability in mice) and the tested non-severely toxic dose reaches 200 mg/kg in mice. M1-21 also has low hemolytic toxicity and immunogenicity in mice. Conclusions M1-21 is a promising interfering peptide targeting FOXM1 for the development of anti-cancer drugs.

show abstract

Oncofetal protein IGF2BP1 regulates IQGAP3 expression to maintain stem cell potential in cancer

Cited by 8 publications

References 61 publications

Protocol for identification and validation of IGF2BP1 target genes in pluripotent human embryonic carcinoma cells

Protocol for identification and validation of IGF2BP1 target genes in pluripotent human embryonic carcinoma cells

The roles of m6A RNA methylation modification in cancer stem cells: new opportunities for cancer suppression

The development of an anti-cancer peptide M1-21 targeting transcription factor FOXM1

Contact Info

Product

Resources

About